Zecotek’s switchable 3D/2D optical imaging system granted U.S. Patent

NewsGuard 100/100 Score

Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for industrial, healthcare and scientific markets, is pleased to announce that the U.S. Patent office has granted U.S. Patent No. 9,055,288 to Zecotek for technology related to the Company's switchable 3D/2D optical imaging system. This patent adds to the global portfolio of patents, including U.S. patent number 7,944,465 covering Zecotek's glasses-free 3D auto-stereoscopic display system.

"This U.S. patent marks another important step in our continued efforts to provide the best-in-class glasses-free 3D displays and monitors," said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. "The patent covers the significant improvements to our switchable 3D/2D display technology which meet the practical needs of OEM's and end users. Our 3D display technology allows for switching between 3D and 2D modes without loss of resolution, and displaying 3D and 2D content simultaneously. The patent also covers technology which significantly broadens the capabilities of specialized 3D display applications such as fundamental research and medical imaging. We are working closely with OEM's within well-defined markets and will continue to maintain an aggressive IP development program in parallel with our efforts to meet market requirements."

The 3D/2D switchable optical imaging system further improves the core capabilities of the 3D display technology by introducing a software-selectable full-resolution 2D mode with viewing angles and dynamic range/colour depth on par with conventional 2D displays. The patent also covers technology for both 3D and 2D modes, dynamic adjustment of viewing angle, number and width of viewing zones as well as the functionality to dynamically control the positioning of different viewing zones.

Patents have been granted to Zecotek for its 3D display system in the United States, China, Europe, Eurasia, Russia and Australia. Other patents have been filed and are pending in Japan, Korea and India.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New research pinpoints key pathways in prostate cancer's vulnerability to ferroptosis